Homology Medicines, Inc.
NASDAQ:FIXX
0.9347 (USD) • At close March 25, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 1.156 | 3.208 | 33.971 | 2.702 | 1.666 | 3.684 | 0 | 0 |
| Cost of Revenue
| 0 | 0.578 | 2.599 | 9.544 | 100.392 | 89.398 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0.578 | 0.609 | 24.427 | -97.69 | -87.732 | 3.684 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0.5 | 0.19 | 0.719 | -36.155 | -52.66 | 1 | 0 | 0 |
| Reseach & Development Expenses
| 48.143 | 62.002 | 98.351 | 93.085 | 100.392 | 89.398 | 47.948 | 21.378 | 5.695 |
| General & Administrative Expenses
| 17.959 | 31.256 | 38.138 | 36.835 | 32.573 | 22.211 | 17.3 | 8.279 | 4.305 |
| Selling & Marketing Expenses
| 0 | -0.578 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 17.959 | 30.678 | 38.138 | 36.835 | 32.573 | 22.211 | 17.3 | 8.279 | 4.305 |
| Other Expenses
| 0 | 9.327 | 0 | 0 | 0 | 0 | 0 | -0.876 | 1.929 |
| Operating Expenses
| 66.102 | 92.68 | 136.489 | 129.92 | 132.965 | 111.609 | 65.248 | 29.657 | 10 |
| Operating Income
| -66.102 | -92.102 | -133.281 | -95.949 | -130.263 | -109.943 | -61.564 | -29.657 | -10 |
| Operating Income Ratio
| 0 | -79.673 | -41.546 | -2.824 | -48.21 | -65.992 | -16.711 | 0 | 0 |
| Total Other Income Expenses Net
| 20.015 | 14.349 | 134.479 | 0.185 | 1.569 | 6.027 | 4.349 | -0.333 | 1.953 |
| Income Before Tax
| -46.087 | -87.08 | 1.198 | -95.764 | -128.694 | -103.916 | -57.215 | -29.991 | -8.047 |
| Income Before Tax Ratio
| 0 | -75.329 | 0.373 | -2.819 | -47.629 | -62.375 | -15.531 | 0 | 0 |
| Income Tax Expense
| -0.021 | 25.881 | 0.715 | -0.185 | -1.569 | -6.027 | 4.349 | -0.543 | -0.024 |
| Net Income
| -47.733 | -112.961 | 0.483 | -95.579 | -127.125 | -97.889 | -57.215 | -29.991 | -8.047 |
| Net Income Ratio
| 0 | -97.717 | 0.151 | -2.814 | -47.048 | -58.757 | -15.531 | 0 | 0 |
| EPS
| -5.12 | -351.57 | 1.51 | -311.2 | -498.41 | -418.35 | -360.7 | -159.96 | -77.86 |
| EPS Diluted
| -4.94 | -351.57 | 1.51 | -311.2 | -498.41 | -418.35 | -360.7 | -159.96 | -77.86 |
| EBITDA
| -66.102 | -91.524 | -133.281 | -87.596 | -122.298 | -103.625 | -60.275 | -28.973 | -9.76 |
| EBITDA Ratio
| 0 | -79.173 | -41.546 | -2.579 | -45.262 | -62.2 | -16.361 | 0 | 0 |